The results showed that exogenous NFKB1 overexpression significantly inhibited FOXS1 expression at both the mRNA (Fig. 7G) and protein (Fig. 7H) levels, suggesting that exogenous NFKB1 may be an effective treatment strategy targeting FOXS1 in GC patients. Here, FOXS1 is linked to gastric cancer.